Arginine/lysine not checked
Advanced Accelerator Applications
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “1000 milliliters (mL) administered at a constant rate of 250 mL per hour”In the company’s words, NCT04524442 on ClinicalTrials.gov
- Main trialPhase 4
- “The purpose of the study was to evaluate the effect of arginine/lysine solution administration on serum potassium levels. A systematic assessment of serum potassium levels was performed during infusion and up to 24 hours post start of infusion compared to baseline.”In the company’s words, NCT04524442 on ClinicalTrials.gov
- Other names
- LysaKare
Other drugs for Gastroenteropancreatic Neuroendocrine Tumors
- CAM2029Camurus AB · Phase 3
- RYZ101RayzeBio, Inc. · Phase 3
- 177Lu-edotreotide PRRTITM Solucin GmbH · Phase 3
- VMT-α-NETPerspective Therapeutics · Phase 1/2
- CVM-1118TaiRx, Inc. · Phase 2
- Lu-DOTA-TATENovartis · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 4Completed | 18 Nov 2023 | Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026